Vorasidenib citrate
Term · Oncology and biomedicine · MLC-T-ONC-009316
A drug used to treat adults and children aged 12 years and older with grade 2 astrocytoma or oligodendroglioma (types of brain tumors) that has an abnormal IDH1 or IDH2 gene. It is used in patients who had a biopsy or surgery to remove the tumor. It is also being studied in the treatment of other types of cancer. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep cancer cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Also called Voranigo.
The hemicitrate, hemihydrate form of vorasidenib, an orally available inhibitor of wild-type (WT) and mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically targets and inhibits WT and mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 or IDH2 mutations and/or overexpressing IDH1 or IDH2. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB). IDH1 and 2, metabolic enzymes that catalyze the conversion of isocitrate into a-KG, play key roles in energy production and are mutated in a variety of cancer cell types. In addition, mutant forms of IDH1 and 2 catalyze the formation of 2HG and drive cancer growth by blocking cellular differentiation and inducing cellular proliferation.
| Identifier | MLC-T-ONC-009316 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Voranigo; vorasidenib hemicitric acid hemihydrate |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009316",
"term": "Vorasidenib citrate",
"field": "Oncology and biomedicine",
"definitions": [
"A drug used to treat adults and children aged 12 years and older with grade 2 astrocytoma or oligodendroglioma (types of brain tumors) that has an abnormal IDH1 or IDH2 gene. It is used in patients who had a biopsy or surgery to remove the tumor. It is also being studied in the treatment of other types of cancer. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep cancer cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Also called Voranigo.",
"The hemicitrate, hemihydrate form of vorasidenib, an orally available inhibitor of wild-type (WT) and mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically targets and inhibits WT and mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 or IDH2 mutations and/or overexpressing IDH1 or IDH2. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB). IDH1 and 2, metabolic enzymes that catalyze the conversion of isocitrate into a-KG, play key roles in energy production and are mutated in a variety of cancer cell types. In addition, mutant forms of IDH1 and 2 catalyze the formation of 2HG and drive cancer growth by blocking cellular differentiation and inducing cellular proliferation."
],
"synonyms": [
"Voranigo",
"vorasidenib hemicitric acid hemihydrate"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vorasidenib-citrate/"
}
Record 17,337 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.